NYSE MKT LLC · IGC
+6.98% · +$0.0200 · Vol 811.7K
Market closed · last close 4:00 PM ET · price as of 20:00:00 ET
IGC Pharma Inc

IGC Pharma Inc

Pharmaceuticals
$0.2850
Card
Relationship Map

Follow $IGC

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $IGC by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
IGC
IGC Pharma Inc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

62/ 100
Veridion Score
Upper range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IGC moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IGC catalysts
About IGC Pharma Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2006
Employees
70
Country
US

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.2663
Day high
$0.2875
Day low
$0.2663
Previous close
$0.2664
52W high
$0.4240
-32.78% from high
52W low
$0.2400
24% of range
Market cap
$29.5M
EPS
$-0.0933
Beta
1.17
Shares out
103.4M
Volume
811.7K
0.86× rel vol
Avg volume
949K
VWAP
$0.2793
Price history computed in-house
1W
+2.30%
1M
-7.47%
3M
+6.90%
1Y
-30.32%
YTD
+1.28%
SMA 50 $0.2768 · above
SMA 200 $0.2864 · below
52W position 24%

IGC overview

Veridion Score
62
Registered · 2026-09-18
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around IGC.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading IGC Form 4 filings
Public disclosures

Congress activity in IGC

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for IGC in the cached public ledger.

Federal contracts

IGC contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IGC in this window.
Lobbying spend

IGC lobbying filings, year to date.

Registered lobbying filings matched to IGC Pharma Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IGC in this window.
Loading news for IGC
Analyst ratings
Sovereign unlock shows live analyst consensus for IGC.
Options
Sovereign unlock shows live options positioning for IGC.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.